HomeCompareBOMOD vs ABBV

BOMOD vs ABBV: Dividend Comparison 2026

BOMOD yields 4444.44% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BOMOD wins by $19857738408180.38M in total portfolio value
10 years
BOMOD
BOMOD
● Live price
4444.44%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19857738408180.48M
Annual income
$19,016,069,933,146,186,000.00
Full BOMOD calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BOMOD vs ABBV

📍 BOMOD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBOMODABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BOMOD + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BOMOD pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BOMOD
Annual income on $10K today (after 15% tax)
$377,777.78/yr
After 10yr DRIP, annual income (after tax)
$16,163,659,443,174,257,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, BOMOD beats the other by $16,163,659,443,174,236,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BOMOD + ABBV for your $10,000?

BOMOD: 50%ABBV: 50%
100% ABBV50/50100% BOMOD
Portfolio after 10yr
$9928869204090.29M
Annual income
$9,508,034,966,573,105,000.00/yr
Blended yield
95.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BOMOD
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BOMOD buys
0
ABBV buys
0
No recent congressional trades found for BOMOD or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBOMODABBV
Forward yield4444.44%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$19857738408180.48M$102.3K
Annual income after 10y$19,016,069,933,146,186,000.00$24,771.77
Total dividends collected$19800558376185.16M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BOMOD vs ABBV ($10,000, DRIP)

YearBOMOD PortfolioBOMOD Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$455,144$444,444.44$11,550$430.00+$443.6KBOMOD
2$19,392,277$18,905,272.87$13,472$627.96+$19.38MBOMOD
3$773,548,232$752,798,494.96$15,906$926.08+$773.53MBOMOD
4$28,891,953,466$28,064,256,857.57$19,071$1,382.55+$28891.93MBOMOD
5$1,010,538,077,568$979,623,687,360.21$23,302$2,095.81+$1010538.05MBOMOD
6$33,103,483,882,921$32,022,208,139,922.89$29,150$3,237.93+$33103483.85MBOMOD
7$1,015,787,352,937,823$980,366,625,183,097.90$37,536$5,121.41+$1015787352.90MBOMOD
8$29,201,617,438,828,424$28,114,724,971,184,950.00$50,079$8,338.38+$29201617438.78MBOMOD
9$786,606,051,433,916,900$755,360,320,774,370,600.00$69,753$14,065.80+$786606051433.85MBOMOD
10$19,857,738,408,180,478,000$19,016,069,933,146,186,000.00$102,337$24,771.77+$19857738408180.38MBOMOD

BOMOD vs ABBV: Complete Analysis 2026

BOMODStock

bowmo, Inc. provides an intelligent software solution for staffing and recruiting industries. The company offers recruiting software and services through an online AI-driven platform to connect potential candidates to employers for all businesses. It also provides managed recruiting as a service, which allows clients to outsource the management of the recruiting process. bowmo, Inc. was founded in 2015 and is headquartered in New York, New York.

Full BOMOD Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BOMOD vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BOMOD vs SCHDBOMOD vs JEPIBOMOD vs OBOMOD vs KOBOMOD vs MAINBOMOD vs JNJBOMOD vs MRKBOMOD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.